L3VLUP
ProSign in

HRMY · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

HRMYLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • HRMY
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterHRMYLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 20201 holders, $3.9m29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 20211 holders, $66m31 holders, $34.7bn
Q1 20222 holders, $87m24 holders, $35.3bn
Q2 20223 holders, $92m33 holders, $42.7bn
Q3 20223 holders, $93m31 holders, $43.4bn
Q4 20225 holders, $110m31 holders, $46.6bn
Q1 20233 holders, $16m33 holders, $44.3bn
Q2 20235 holders, $35m37 holders, $59.6bn
Q3 20235 holders, $28m44 holders, $67.6bn
Q4 20234 holders, $23m45 holders, $73.6bn
Q1 20242 holders, $15m41 holders, $95.3bn
Q2 20241 holders, $2.6m43 holders, $110bn
Q3 20242 holders, $3.4m45 holders, $107bn
Q4 20243 holders, $35m46 holders, $93.9bn
Q1 20253 holders, $36m42 holders, $98.4bn
Q2 20251 holders, $38m43 holders, $93.2bn
Q3 20254 holders, $7.5m39 holders, $86.7bn
Q4 20255 holders, $111m41 holders, $123bn
Q1 20265 holders, $41m39 holders, $106bn
Q2 20263 holders, $54m44 holders, $132bn
HRMY

Harmony Biosciences HLDGS In

Holders
4
Reported value
$23m
Buyers
3
Sellers
1

Breadth +2 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
45
Reported value
$73.6bn
Buyers
27
Sellers
21

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only HRMY (3)

PDT Partners LLC, Voloridge Investment Management LLC, Winton Group Ltd

Only LLY (44)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, and 19 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →